Does the Veterans Affairs depression performance measure predict quality care?

BACKGROUND: In 2000, the Department of Veterans Affairs (VA) instituted a performance measure to improve the quality of depression care. The measure evaluated adequacy of follow-up for depressed patients but was removed from clinic directors' performance plans in fiscal year (FY) 2009 because it had not been empirically validated. The VA depression performance measure was compared with an empirically validated model for assessing adherence to important depression treatment processes. METHODS: VA medical centers (VAMCs) whose performance on the VA depression measure was in the top or bottom quartile nationally for all four quarters in FY2008 were selected for inclusion. A blinded interviewer attempted to contact clinical directors of both primary care and mental health at each VAMC and conducted telephone interviews using a protocol designed to employ the 3-Component Model (3CM) fidelity measure, which assesses domains of evidence-based depression care. RESULTS: There were 9 sites in the "high-performing" group and 10 sites in the "low-performing" group. At least one interview was completed at 8 of the 9 sites in the high-performing group and 9 of the 10 sites in the low-performing group. There was a significant difference in the percentage of patients meeting the VA depression performance measure between the high- and low-performing groups (47.5% versus 14.7%; chi2 = 837.5, p < .001). The adapted version of the 3CM fidelity scale detected a significant difference in process of depression care between the high- and low-performing sites (82.3 versus 71.4; z = 2.4, p = .018). CONCLUSIONS: The highest-performing sites on the VA depression performance measure adhered to important care processes more often than did the lowest-performing sites.

The role of passenger leukocyte genotype in rejection and acceptance of rat liver allografts.

BACKGROUND: Although graft-resident passenger leukocytes are known to mediate acute rejection by triggering direct allorecognition, they may also act in an immunomodulatory fashion and play an important role in tolerance induction. Our purpose in the current study was to utilize rat bone marrow chimeras to evaluate the role of the genotype of passenger leukocytes in both acute rejection and tolerance of liver allografts. METHODS: The fate of livers bearing donor-type, recipient-type, and third-party passenger leukocytes was evaluated in the MHC class I and II mismatched rejector combination ACI-->LEW and the acceptor combination PVG-->DA. RESULTS: We report that although treatment of ACI liver donors with lethal irradiation does not lead to prolongation of graft survival in the ACI-->LEW strain combination, ACI livers bearing recipient-type (LEW) or third-party passenger leukocytes (BN) are rejected at a significantly slower rate. We confirm that lethal irradiation of PVG donor animals leads to abrogation of tolerance induction with acute rejection of their livers by DA recipients. However, the majority of PVG livers carrying donor-type (PVG), recipient-type (DA), or third-party (LEW) passenger leukocytes are accepted for >100 days. These DA recipients develop immune tolerance to the donor parenchyma (PVG). CONCLUSIONS: Our findings demonstrate that long-term acceptance of liver allografts and tolerance induction is not dependent on the presence of donor-type passenger leukocytes and can be achieved with organs carrying donor-type, recipient-type, or third-party passenger leukocytes. The importance of the MHC framework on the surface of passenger leukocytes as a critical regulator of the immune response after transplantation of chimeric organs is substantiated by the delayed tempo of rejection of ACI livers bearing recipient-type or third-party passenger leukocytes in the ACI-->LEW strain combination.